Navigating the Complex World of AI in Regulated Industries

AI Laws and Classifications: A Global Perspective

AI regulations are evolving rapidly, with different approaches being adopted worldwide. The European Union (EU), for example, has implemented the AI Act, a holistic regulation that provides a framework for AI systems. However, this approach can sometimes lack specificity, requiring additional guidance from industry-specific regulatory agencies.

In contrast, countries like South Korea have introduced the Basic Act on AI Advancement and Trust, reemphasizing the EU’s focus on human-centric and extraterritorial applications. These laws aim to enhance competitiveness, quality of life, and protection of individual rights.

The EU has made strides in regulating AI in medicine through the European Medicines Agency’s AI Work Plan. This initiative guides the use of AI in medicine regulation, focusing on:

• Guidance, policy, and product support
• Tools and technology
• Collaboration and Change management and
• Experimentation

A publication from last year (Reflection paper on the use of Artificial Intelligence (AI) in the medicines product lifecycle) emphasized the need for companies to proactively manage AI risks throughout the medicine product lifecycle.

 

AI Innovation and Regulatory Use in Healthcare

AI’s potential in healthcare is immense, with over 1,000 AI-enabled medical devices approved in the U.S. alone. The focus remains on ensuring safety and effectiveness, particularly in high-risk areas like radiology and cardiovascular health. The FDA has also released guidelines on using AI for regulatory decision-making concerning drug safety and efficacy.

 

 

Implementing AI models poses several challenges, particularly in credibility assessment and risk management. A well-executed credibility assessment plan is essential, involving:

1. Risk analysis
2. Model validation
3. Documentation of results

Early engagement with regulatory bodies, like the FDA, can help set expectations and address specific challenges.

Achieving ISO certification for AI systems is fraught with challenges due to the dynamic regulatory landscape and the complexity of AI systems. Currently, only a handful of companies hold this certification, highlighting the need for tailored oversight.

 

“ISO 42001 certification provides consistency and assurance of quality, but implementation remains challenging.” Nikodem Latocha

 

AI risk management is a critical component of AI governance. The National Institute of Standards and Technology’s AI Risk Management Framework (NIST AI RMF) offers a structured approach to managing AI-related risks. Even though it has been designed as industry-agnostic, it can be successfully adopted in the pharmaceutical industry, offering a structured and consistent approach regarding patient safety, product quality, and data integrity.

The integration of AI in regulated industries like healthcare brings several challenges:

• Alignment with the evolving regulatory landscape
• Ensuring continuous compliance
• Managing resource constraints
• Integration of complex AI systems with the existing  legacy systems and processes without disrupting the operations

Despite these challenges, the regulated industries, including pharma, need to be prepared for the upcoming transformation and impact of AI-enabled systems.

 

Conclusion

The integration of AI into regulated industries is reshaping efficiency and compliance standards. While the challenges are significant, the potential for AI to revolutionize processes and improve patient safety is immense. As regulations evolve, companies must focus on governance, risk management, and collaboration to harness AI’s full potential.

AI will have a groundbreaking role in the near future, reshaping the way we do and think about various GXP processes.

By staying informed and proactive, industries can navigate the complexities of AI regulations and embrace the innovations that will drive future advancements.

 

How PrimeVigilance Can Help

Selecting the right pharmacovigilance partner is a strategic decision—especially when adopting innovative technologies like Artificial Intelligence to enhance drug safety operations. At PrimeVigilance, we support sponsors by combining scientific expertise with proven operational excellence to guide the responsible and effective integration of AI into pharmacovigilance systems.

Contact PrimeVigilance today to discuss how we can support your organization’s pharmacovigilance needs.